Aton Health’s Funding Fuels a Strategic Shift in Clinical Research

KANSAS CITY, Mo. – June 12, 2026 – Aton Health, a company pioneering the integration of clinical research into routine patient care, today announced the closing of a significant Series A growth investment. The round, led by the healthcare-focused investment platform Shore Search Partners, is more than a simple capital injection; it represents a powerful validation of a business model poised to fundamentally reshape how real-world evidence is generated and utilized across the healthcare industry.

The investment will accelerate the expansion of Aton Health's TrialSight™ and CareSight™ platforms, enabling the Kansas City-based company to move beyond its initial success in gastroenterology and into new medical specialties. For business leaders and investors, this move signals a pivotal moment in the evolution of clinical research, shifting the paradigm from siloed, centralized trials to a more democratic, efficient, and integrated system.

A New Paradigm for Real-World Evidence

For decades, the clinical research process has been largely separate from everyday patient care, creating significant barriers to participation for both patients and providers. Traditional trial sites are often concentrated in major academic centers, limiting access for a vast majority of the population and resulting in data that may not be representative of real-world patient diversity. This friction slows down medical innovation and creates a lag between discovery and implementation.

Aton Health is tackling this challenge head-on by embedding its data collection infrastructure directly into existing specialty practices. The company’s model focuses on non-interventional research, allowing providers to participate in studies, screen patients, and generate high-quality data without disrupting their established clinical workflows. With a platform that already screens tens of thousands of patients monthly and has enrolled over 5,000 active participants, Aton has demonstrated a scalable solution to a long-standing industry problem.

"Our mission is to make healthcare research more accessible, actionable, and representative," said Tom Sanders, CEO and Co-Founder of Aton Health, in the announcement. He emphasized that the investment from a sophisticated healthcare investor like Shore Search Partners validates their approach, which builds research models that "fit naturally within care delivery and provide sponsors with access to high-quality, real-world data."

Aton’s technology suite, including the TrialSight™ screening intelligence platform and the CareSight™ evidence activation platform, forms the operational backbone of this model. TrialSight™ integrates clinician-led workflows into the point of care, enabling rapid patient identification and enrollment. Meanwhile, CareSight™ aims to close the loop by creating pathways to translate the generated evidence back into the standard of care, ensuring that insights lead to tangible improvements in patient outcomes.

The Strategic Bet: Why Shore Search Partners Invested

The decision by Shore Search Partners to lead this round is a calculated bet on a burgeoning market. The global markets for Decentralized Clinical Trials (DCTs) and Real-World Evidence (RWE) are experiencing explosive growth. Projections show the DCT market soaring to nearly $19 billion by 2030, while the RWE solutions market is expected to surpass $10 billion in the same timeframe. This growth is fueled by regulatory tailwinds, the proliferation of digital health infrastructure, and an industry-wide demand for faster, more diverse, and more cost-effective drug development pathways.

Shore Capital Partners, the parent firm of Shore Search Partners with approximately $17 billion in assets under management, has a long history of making strategic investments in high-growth, lower-middle market healthcare companies. Their investment in Aton Health aligns perfectly with this strategy.

Cameron Perkins, a Partner at Shore Search Partners, articulated the strategic thesis clearly. "The future of clinical research depends on making participation more accessible to patients while minimizing operational burden on providers," he stated. "Aton is helping close that gap by embedding research into routine care through a scalable platform that expands patient access, fits naturally within clinical workflows, and generates broader and more representative real-world evidence."

This investment is not just about backing a promising technology; it's about backing a new operational model that addresses the core inefficiencies of the current system. By removing friction for providers and democratizing access for patients, Aton Health is positioned to capture significant value in a market ripe for disruption.

From Gastroenterology to a Broader Horizon

Aton Health has already built a powerful operational engine in the field of gastroenterology, partnering with major provider groups like Gastro Health and GI Alliance on large-scale observational studies. This initial focus allowed the company to prove the efficacy and scalability of its model in a complex specialty.

The Series A funding provides the fuel to replicate this success across other critical areas of healthcare. While the company has not detailed its full expansion roadmap, its mission points toward tackling major public health challenges like cancer screening and chronic disease management. The adaptability of its platform means that the processes honed in gastroenterology can be applied to other specialties that rely on routine screenings and longitudinal patient monitoring, such as oncology, cardiology, and pulmonology.

This expansion represents the next phase of Aton's strategic growth. By entering new markets, the company not only diversifies its revenue streams but also amplifies its impact, generating a richer, more varied dataset that can accelerate discoveries across multiple disease states. The ability to execute this expansion will be a key indicator of the platform's long-term competitive advantage.

Redefining the Ecosystem for Patients and Providers

The ultimate impact of Aton Health's innovation lies in its ability to create a win-win-win scenario for patients, providers, and research sponsors. For patients, particularly those in rural or underserved communities, this model opens the door to research opportunities that were previously out of reach. It transforms a routine doctor's visit into a potential gateway for contributing to medical science.

For healthcare providers, Aton’s clinician-led approach offers a way to become active participants in cutting-edge research without taking on the prohibitive administrative and operational burdens of running a traditional trial site. This empowers them to contribute to the evidence base that will shape the future of their own practice.

While Aton Health operates in a competitive space alongside other companies aiming to integrate research into care, its sharp focus on non-interventional studies and seamless workflow integration provides a distinct edge. As Aton Health scales its operations with this new capital, the broader healthcare industry will be watching closely to see if this integrated model becomes the new standard for generating evidence and accelerating medical innovation.